EleftheriosPMamounasMD

PubMed

• Evaluating Regional Nodal Irradiation Allocation and Association with Oncologic Outcomes in NSABP B-18, B-27, B-40, and B-41.
  Raymond B Mailhot Vega, Shu Wang, Eric D Brooks, Oluwadamilola T Oladeru, Natalie A Lockney, Lisa E Spiguel, Shannon M MacDonald, Eleftherios P Mamounas, Nancy P Mende...> ;International journal of radiation oncology, biology, physics. 2022 Jul 1
• 12 citations
  Trastuzumab for early-stage, HER2-positive breast cancer: a meta-analysis of 13 864 women in seven randomised trials
  Rosie Bradley, Jeremy P Braybrooke, Richard Gray, Robert Kerrin Hills, Z Liu, Richard Peto, Lucy Davies, David Dodwell, Paul McGale, Hongchao Pan, Carolyn W. Taylor, S...> ;Lancet Oncology. 2021 Aug 1
• Characteristics of residual invasive breast cancer after neoadjuvant therapy in the KATHERINE study.
  Eleftherios P. Mamounas> ;Annals of Oncology. 2021 May 29
• 2 citations
  MAF Amplification and Adjuvant Clodronate Outcomes in Early-Stage Breast Cancer in NSABP B-34 and Potential Impact on Clinical Practice.
  Alexander H.G. Paterson, Peter C. Lucas, Stewart J. Anderson, Eleftherios P. Mamounas, Adam Brufsky, Luis Baez-Diaz, Karen M. King, Thomas E. Lad, André Robidoux, Mela...> ;JNCI Cancer Spectrum. 2021 May 28
• 1 citations
  NRG Oncology/NSABP B-47 menstrual history study: impact of adjuvant chemotherapy with and without trastuzumab.
  Patricia A. Ganz, Reena S. Cecchini, Louis Fehrenbacher, Charles E. Geyer, Priya Rastogi, John Crown, M. Thirlwell, David M. Ellison, Jean Francois Boileau, Patrick J....> ;NPJ breast cancer. 2021 May 20
• 10 citations
  Adjuvant T-DM1 versus trastuzumab in patients with residual invasive disease after neoadjuvant therapy for HER2-positive breast cancer: subgroup analyses from KATHERINE.
  Eleftherios P. Mamounas, Michael Untch, Max S. Mano, C.-S. Huang, Charles E. Geyer, G. von Minckwitz, Norman Wolmark, Xavier Pivot, S. Kuemmel, Michael P. DiGiovanna, ...> ;Annals of Oncology. 2021 Aug 1
• A qualitative study to evaluate physician attitudes regarding omission of surgery among exceptional responders to neoadjuvant systemic therapy for breast cancer (NRG-C...
  L.A. Gharzai, Lauren A. Szczygiel, Dean A. Shumway, Hanna Bandos, Thomas B. Julian, Eleftherios P. Mamounas, Julia White, Jennifer F. De Los Santos, Mark Basik, Patric...> ;Breast Cancer Research and Treatment. 2021 Mar 19
• 5 citations
  Comparison of Radiation With or Without Concurrent Trastuzumab for HER2-Positive Ductal Carcinoma In Situ Resected by Lumpectomy: A Phase III Clinical Trial.
  Melody A. Cobleigh, Stewart J. Anderson, Kalliopi P. Siziopikou, Douglas W. Arthur, Rachel Rabinovitch, Thomas B. Julian, David S. Parda, Samantha A. Seaward, Dennis L...> ;Journal of Clinical Oncology. 2021 Mar 19
• 55 citations
  Palbociclib with adjuvant endocrine therapy in early breast cancer (PALLAS): interim analysis of a multicentre, open-label, randomised, phase 3 study.
  Erica L. Mayer, Amylou C. Dueck, Miguel Martín, G. Rubovszky, Harold J. Burstein, Meritxell Bellet-Ezquerra, Kathy D. Miller, Nicholas Zdenkowski, Eric P. Winer, Georg...> ;Lancet Oncology. 2021 Feb 1
• 4 citations
  Advances in Therapeutic Approaches for Triple-Negative Breast Cancer.
  Reshma Mahtani, Muaiad Kittaneh, Kevin Kalinsky, Eleftherios P. Mamounas, Sunil Badve, Charles L. Vogel, Elyse E. Lower, Lee S. Schwartzberg, Mark D. Pegram> ;Clinical Breast Cancer. 2021 Oct 1
• 1 citations
  Validation of the NSABP/NRG Oncology 8-Gene Trastuzumab-benefit Signature in Alliance/NCCTG N9831.
  Katherine L. Pogue-Geile, Nan Song, Daniel J. Serie, Ying Wang, Patrick G. Gavin, Rim S. Kim, Noriko Tanaka, Debora Fumagalli, Yusuke Taniyama, Zhuo Li, Priya Rastogi,...> ;JNCI Cancer Spectrum. 2020 Sep 7
• 5 citations
  NSABP B-41, a Randomized Neoadjuvant Trial: Genes and Signatures Associated with Pathologic Complete Response
  Sandra M. Swain, Gong Tang, Heather Ann Brauer, David Goerlitz, Peter C. Lucas, André Robidoux, Brent T. Harris, Hanna Bandos, Yuqi Ren, Charles E. Geyer, Priya Rastog...> ;Clinical Cancer Research. 2020 Aug 15
• 8 citations
  Patient-reported outcomes from KATHERINE: A phase 3 study of adjuvant trastuzumab emtansine versus trastuzumab in patients with residual invasive disease after neoadju...
  Pierfranco Conte, Andreas Schneeweiss, Sibylle Loibl, Eleftherios P. Mamounas, Gunter von Minckwitz, Max S. Mano, Michael Untch, Chiun-Sheng Huang, Norman Wolmark, Pri...> ;Cancer. 2020 Jul 1
• 8 citations
  A Roundtable Discussion of the Breast Cancer Therapy Expert Group (BCTEG): Clinical Developments and Practice Guidance on Human Epidermal Growth Factor Receptor 2 (HER...
  Reshma Mahtani, Frankie-Ann Holmes, Sunil Badve, Humberto Caldera, Robert E. Coleman, Eleftherios P. Mamounas, Kevin Kalinsky, Muaiad Kittaneh, Elyse E. Lower, Mark D....> ;Clinical Breast Cancer. 2020 Jun 1
• 2 citations
  Molecular Predictive and Prognostic Markers in Locoregional Management
  Eleftherios P. Mamounas, Melissa Mitchell, Wendy A. Woodward> ;Journal of Clinical Oncology. 2020 May 22
• 2 citations
  Clinical Trials for the Surgical Oncologist: Opportunities and Hurdles
  Ko Un Park, Eleftherios P. Mamounas, Matthew H.G. Katz, Gary Unzeitig, Darren R. Carpizo, Y. Nancy You, Amanda B. Francescatti, Kelly K. Hunt, Judy C. Boughey> ;Annals of Surgical Oncology. 2020 Jul 1
• 108 citations
  Management of Cancer Surgery Cases During the COVID-19 Pandemic: Considerations.
  David L. Bartlett, James R. Howe, George J. Chang, Aimee M. Crago, Melissa E. Hogg, Giorgos C. Karakousis, Edward A. Levine, Ajay V. Maker, Eleftherios P. Mamounas, Ka...> ;Annals of Surgical Oncology. 2020 Apr 8
• 3 citations
  Management of Hereditary Breast Cancer: ASCO, ASTRO, and SSO Guideline.
  Kandace P. McGuire, Eleftherios P. Mamounas> ;Annals of Surgical Oncology. 2020 Apr 3
• NSABP B-47/NRG Oncology Phase III Randomized Trial Comparing Adjuvant Chemotherapy With or Without Trastuzumab in High-Risk Invasive Breast Cancer Negative for HER2 by...
  Fehrenbacher, L., Cecchini, R. S., Geyer, C. E., Rastogi, P., Costantino, J. P., Atkins, J. N., Crown, J. P., Polikoff, J., Boileau, J., Provencher, L., Stokoe, C., Mo...> ;Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2019 Dec 11
• 9 citations
  Case-Based Review and Clinical Guidance on the Use of Genomic Assays for Early-Stage Breast Cancer: Breast Cancer Therapy Expert Group (BCTEG).
  Muaiad Kittaneh, Sunil Badve, Humberto Caldera, Robert E. Coleman, Matthew P. Goetz, Reshma Mahtani, Eleftherios P. Mamounas, Kevin Kalinsky, Elyse E. Lower, Mark D. P...> ;Clinical Breast Cancer. 2020 Jan 8
• 148 citations
  Long-term primary results of accelerated partial breast irradiation after breast-conserving surgery for early-stage breast cancer: a randomised, phase 3, equivalence t...
  Frank A. Vicini, Reena S. Cecchini, Julia White, Douglas W. Arthur, Thomas B. Julian, Rachel Rabinovitch, Robert R. Kuske, Patricia A. Ganz, David S. Parda, Michael F....> ;The Lancet. 2019 Dec 14
• 5 citations
  Toronto Workshop on Late Recurrence in Estrogen Receptor-Positive Breast Cancer: Part 2: Approaches to Predict and Identify Late Recurrence, Research Directions.
  Ryan J.O. Dowling, Joseph A. Sparano, Pamela J. Goodwin, François-Clément Bidard, David W. Cescon, Sarat Chandarlapaty, Joseph O. Deasy, Mitch Dowsett, Robert Gray, N....> ;JNCI Cancer Spectrum. 2019 Dec 1
• 8 citations
  Toronto Workshop on Late Recurrence in Estrogen Receptor-Positive Breast Cancer: Part 1: Late Recurrence: Current Understanding, Clinical Considerations.
  Ryan J.O. Dowling, Kevin Kalinsky, Daniel F. Hayes, François-Clément Bidard, David W. Cescon, Sarat Chandarlapaty, Joseph O. Deasy, Mitch Dowsett, Robert Gray, N. Lynn...> ;JNCI Cancer Spectrum. 2019 Dec 1
• 16 citations
  Pathologic complete response and outcomes by intrinsic subtypes in NSABP B-41, a randomized neoadjuvant trial of chemotherapy with trastuzumab, lapatinib, or the combi...
  Sandra M. Swain, Gong Tang, Peter C. Lucas, André Robidoux, David Goerlitz, Brent T. Harris, Hanna Bandos, Charles E. Geyer, Priya Rastogi, Eleftherios P. Mamounas, No...> ;Breast Cancer Research and Treatment. 2019 Aug 19
• Stromal Tumor-infiltrating Lymphocytes in NRG Oncology/NSABP B-31 Adjuvant Trial for Early-stage HER2-positive Breast Cancer.
  Kim, R. S., Song, N., Gavin, P. G., Salgado, R., Bandos, H., Kos, Z., Floris, G., Van den Eynden, G. G., Badve, S., Demaria, S., Rastogi, P., Fehrenbacher, L., Mamouna...> ;Journal of the National Cancer Institute. 2019 Mar 20
• Join now to see all

Journal Articles

• 21-Gene Assay as Predictor of Chemotherapy Benefit in HER2-Negative Breast Cancer  
  Eleftherios P Mamounas, Frederick L Baehner, Norman Wolmark, D Lawrence Wickerham, Nature
• Clinical Relevance of the 21-Gene Recurrence Score® Assay in Treatment Decisions for Patients with Node-Positive Breast Cancer in the Genomic Era  
  Eleftherios Mamounas, MD, Nature

Lectures

• NRG Oncology/NSABP B-51/RTOG 1304: Phase III trial to determine if chest wall and regional nodal radiotherapy (CWRNRT) post mastectomy (Mx) or the addition of RNRT to ... 
  2019 ASCO Annual Meeting - 6/1/2019
• NRG Oncology/NSABP B-51/RTOG 1304: Phase III trial to determine if chest wall and regional nodal radiotherapy (CWRNRT) post mastectomy (Mx) or the addition of RNRT to ... 
  2018 ASCO Annual Meeting - Chicago, Illinois - 06/2/2018